Treatment.Com International Inc. (TREIF)
| Previous Close | 0.0324 |
| Open | 0.0366 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0366 - 0.0366 |
| 52 Week Range | 0.0233 - 0.4059 |
| Volume | |
| Avg. Volume | 5,341 |
| Market Cap | 2.456M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Treatment’s Debut AI-driven Health App Getting Five Star Reviews from Doctors
VANCOUVER, British Columbia, April 06, 2022 (GLOBE NEWSWIRE) -- Treatment.com International Inc. (“Treatment” or the “Company”) (CSE: TRUE; OTC: TREIF; FFA: 939), is a global healthcare company that has developed a next-generation AI platform to help patients and caregivers around the world make better health decisions. Treatment’s landmark debut product, the Treatment Digital Health App, has been garnering five-star reviews on both the Apple App Store and the Google Play Store. Users’ comments
- GlobeNewswire
Treatment Announces Convertible Debenture Private Placement
VANCOUVER, British Columbia, March 28, 2022 (GLOBE NEWSWIRE) -- Treatment.com International Inc. (“Treatment or the “Company”) (CSE: TRUE; OTC: TREIF; FFA: 939), a global healthcare company that has developed a next-generation AI platform to help patients and caregivers around the world make better health decisions, announces the proceeding of a non-brokered private placement, raising aggregate gross proceeds of up to $1,250,000 in unsecured convertible debentures (the “Private Placement”). Each
